Page 1,885«..1020..1,8841,8851,8861,887..1,8901,900..»

Medivet Biologics launches newest service, K9-ACV a personalized medicine approach to canine cancer.

Posted: January 17, 2015 at 7:56 am

Nicholasville, Kentucky (PRWEB) January 16, 2015

MediVet Biologics a company known for their focus on companion animal health with world-class lab facilities was selected by the University of Kentuckys researchers to investigate the potential of a canine cancer treatment. The team of researchers in charge of developing the K-9 ACV veterinary cancer vaccine service have dedicated decades of research toward a better understanding of how the immune system responds to cancer cells with the goal of improving cancer treatment. Leading researcher John Yanelli, Ph.D has spent over 20 years conducting successful NIH-funded clinical trials in humans with lung cancer. Dr. Yannelli has published nearly 100 articles and book chapters on the immunotherapy of human cancer and continues research to improve immunotherapeutic approaches to treat cancer. With this strong knowledge base, this outstanding team now extends their efforts toward developing an effective and affordable personalized cancer vaccine service for veterinary medicine. MediVet Biologics has successfully implemented other cutting edge human medical grade technologies in the Veterinary space such as regenerative medicine in Veterinarian clinics across the world.

Nearly 6 million dogs are diagnosed with cancer every year and greater than fifty percent of dogs over the age of ten will eventually develop cancer, making cancer the leading cause of disease-related death in dogs. Many of the dogs diagnosed have no mode of viable treatment. Cancer screening for early detection in dogs lags far behind human medicine. Consequently, canine cancers are usually diagnosed in later stages of disease, making them more difficult to treat effectively and increasing the likelihood of recurrence. Therapeutic options for treatable tumors include surgery, chemotherapy and radiation therapy. The side effects associated with chemotherapy and radiation therapy can seriously affect quality of life, making it difficult for pet owners to justify current cancer treatments for their dogs. The average cancer treatment expense is over $5,000 and could be well over $35,000.

MediVet Biologics approach is to use the entire tumor cell as the basis for the vaccine. When combined with surgical resection of primary tumors, this activates the immune system, leading to better clinical outcomes for canine cancers. This form of immunotherapy, developed at the NCI by researchers, including Dr. John Yannelli, has been used at the University of Kentucky Markey Cancer Center to treat humans with advanced non-small cell lung cancer (J. Clin Oncol., 22:2808, 2004). Read more about K9-ACV in the February issue of VPN (Veterinary Practice News).

MediVet Biologics reputation and success with in-clinic stem cell therapy adaptation and development make them an excellent fit for an autologous canine tumor vaccine service. The service in which resected tumor tissue will be processed at The University of Kentucky and MediVets lab into a therapeutic vaccine to be administered to dogs with cancer is a personalized medicine approach. MediVet Labs is set-up for state of the art maneuverability with animal biologics as well as superior high-end quality controls, SOPs and protocols.

According to the CEO, Jeremy Delk, MediVet Biologics is excited to make this announcement and offer an additional service to our existing customers as well as future customers. Most of all we look forward to offering an affordable treatment alternative to the animals and owners that need it. This initiative is part of a broader research and development program with MediVet Biologics. Along with the further development and marketing of our veterinary and stem cell business in the United States, more announcements of novel products will come throughout the year.

Veterinarians and patients are being sought in vaccine efficacy studies. To inquire about enrolling a patient please contact MediVet Biologics.

About MediVet Biologics

MediVet Biologics headquartered just outside Lexington, KY and Sydney Australia is a subsidiary of Medical Australia (MLA: ASX). MediVet Biologics has global reach including established partners in 26 countries around the world as well as strong market positioning in North America. The company provides novel treatment options based in science to the Veterinary market and provides unique customer specific service plans to ensure implementation and growth of its progressive products and services.

Medivet Biologics' mission is to set standards of excellence providing biologic solutions to the veterinary market. Our companys success, which is characterized by responsiveness and clinical excellence, has been founded on our dedication and quality innovative technologies. Veterinarians and pet owners trust MediVet Biologics to provide the quality care they expect and deserve. By providing services as though each pet were a member of our family, MediVet Biologics strives to be the preferred provider of Veterinary Regenerative Medicine products, equipment and services.

Read more here:
Medivet Biologics launches newest service, K9-ACV a personalized medicine approach to canine cancer.

Posted in Kentucky Stem Cells | Comments Off on Medivet Biologics launches newest service, K9-ACV a personalized medicine approach to canine cancer.

The 'impossible' dream: City firm's MS claims not medically possible, says top researcher

Posted: January 17, 2015 at 7:54 am

The numbness entered Kathleen Jaynes' body 19 years ago, and during the intervening years the multiple sclerosis symptom has spread from her toes to her chest. Nothing really changes the numbness, or helps. Which is why, despite her sister's misgivings and her own lingering questions, Jaynes paid $20,000 to receive an experimental stem cell procedure in India through Regenetek, a company led by a now-discredited Winnipeg researcher who fudged his credentials and misled patients.

It's not like there are many other sources of hope out there for patients such as Jaynes, 59, who lives in southeast Arizona.

"You're a no-option patient," Jaynes said. "You have no other options. I justified it in every way that I could, despite my family saying this guy is not for real. Unless you're in my numb body, you can't know how desperate you feel to not feel that way."

In exchange for that money, Jaynes and roughly 70 other patients received what one of Canada's top MS researchers calls an "impossible" promise.

In December, Dr. Mark Freedman looked over Regenetek's study protocols, after a reporter drew his attention to the company's claims. Freedman, who is the director of Ottawa Hospital's MS research unit, has plenty of experience with stem cell treatments for the disease: In 2000, he and bone marrow transplant physician Dr. Harold Atkins launched a study to examine whether transplanting stem cells from a patient's own bone marrow could halt the disease.

The study was closely watched, the results tremendously encouraging. The 24 patients in the study -- all of whom had a rapidly advancing form of MS -- showed improvement. Freedman and Atkins also treated about a dozen more patients outside of the study, who have shown the same positive results. The researchers have submitted the study's results for publication in a scientific journal, and are preparing to announce new research sites later this month.

But the procedure Regenetek owner Doug Broeska was touting wasn't anything like the technique that showed such promise in Freedman and Atkins' study.

For instance, Jaynes and other Regenetek patients the Free Press spoke to described having stem cells extracted, expanded and implanted within days of their arrival in Pune, India.

But the premise that patients could receive benefits from stem cells taken from bone marrow extracted just four days earlier -- and which had to make a 300-kilometre round-trip journey between Pune and a lab in Mumbai at that time -- is "impossible," Freedman said.

Culturing and expanding enough of those kind of stem cells is a process that takes "weeks," Freedman said, adding bluntly: "They're not getting anything."

View post:
The 'impossible' dream: City firm's MS claims not medically possible, says top researcher

Posted in Arizona Stem Cells | Comments Off on The 'impossible' dream: City firm's MS claims not medically possible, says top researcher

Stem Cell Treatment Has UC Davis A Step Closer To HIV Cure

Posted: January 17, 2015 at 7:43 am

DAVIS (CBS13) Researchers at UC Davis say they are one step closer to finding a cure for HIV in a breakthrough study for millions around the world living with the virus.

At 60 years old, Paul Curtis looks like the picture of health.

I exercise, eat well get a lot of rest, he said.

But 30 years ago, Curtis was diagnosed as HIV-positive. Doctors told him he might have a year to live, but hes proven them wrong.

With this disease, its imperative that you take the medications consistently, Curtis said.

He relies on medication daily. At one point he took more than 40 pills a day. And he cant miss a dose.

The virus mutates rapidly when you miss doses, he said.

Hes one of millions worldwide waiting for a cure. Previous studies have come close, but none have proven to fight off the virus with stem cell therapy.

Dr. Joe Anderson says he has developed genetically modified human stem cells, which have resisted infection in mice.

When we infected the mice that had these HIV-resistant that had these HIV-resistant immune cells in them, we saw that HIV infection was blocked, he said.

See original here:
Stem Cell Treatment Has UC Davis A Step Closer To HIV Cure

Posted in Stem Cell Therapy | Comments Off on Stem Cell Treatment Has UC Davis A Step Closer To HIV Cure

Spotlight on Muscular Dystrophy and Stem Cell Research – Video

Posted: January 16, 2015 at 9:41 pm


Spotlight on Muscular Dystrophy and Stem Cell Research
Visit: http://www.uctv.tv/) Duchenne muscular dystrophy (DMD) is the most severe form of muscular dystrophy that affects 1 in 3500 boys and leads to progres...

By: University of California Television (UCTV)

Read more:
Spotlight on Muscular Dystrophy and Stem Cell Research - Video

Posted in Stem Cell Research | Comments Off on Spotlight on Muscular Dystrophy and Stem Cell Research – Video

How Can Stem Cell Therapy Help PRP (Platelet Rich Plasma) – Next Generation Stem Cell – Video

Posted: January 16, 2015 at 9:41 pm


How Can Stem Cell Therapy Help PRP (Platelet Rich Plasma) - Next Generation Stem Cell
http://www.nextgenerationstemcell.com Stem Cell Therapy Stem Cell Research.

By: Jasen Kobobel

See more here:
How Can Stem Cell Therapy Help PRP (Platelet Rich Plasma) - Next Generation Stem Cell - Video

Posted in Stem Cell Research | Comments Off on How Can Stem Cell Therapy Help PRP (Platelet Rich Plasma) – Next Generation Stem Cell – Video

Major grant rewards Roswell Park for innovative research into immunotherapy

Posted: January 16, 2015 at 5:55 am

Roswell Park Cancer Institutes cutting-edge research into new therapies for advanced ovarian cancer has received a vote of confidence in the form of a major state grant.

This work shows promise in fighting a particularly deadly form of cancer and could help the Medical Campus develop a reputation as a center for innovative medical research.

The cancer institute has received a four-year, $11.9 million grant from New York State Stem Cell Science. The grant, according to the governors office, is part of a $36 million grant to three research groups for the development of treatments for some of the most devastating conditions that could be helped with stem cell research.

The local award is a nod to Roswell Park and Dr. Kunle Odunsi, executive director of the Center for Immunotherapy. But it is also a nod to the dedicated donors who raise money for the cancer center the Ride for Roswell is just one of many, many examples of those fundraising efforts. Approximately $2 million raised from Western New Yorkers helped to provide the pilot money for Odunsi to get the preliminary data so that he could generate his innovative premise and submit the proposal.

As Candace Johnson, Roswell Parks president and CEO, said, this is an especially important story because it shows how money raised at the grass-roots level has generated a much bigger commitment from the state.

Odunsis concept is so innovative that it might have been difficult to fund through traditional means, whether the National Institutes for Health or National Cancer Institute. That makes the dollars available from the New York State Stem Cell Science critical.

The Roswell Park project involves taking stem cells from the blood of cancer patients, re-engineering them and infusing them back into the patients to become a continuous source of cancer-fighting immune cells.

It is personalized medicine at its best. The Roswell Park team, led by Odunsi, has pushed the envelope of tradition, seeking to develop paradigm-changing therapies for ovarian cancer.

Ovarian cancer is one of the deadliest cancers for women. The American Cancer Society posted estimates for 2015: there will be about 21,290 new cases of ovarian cancer and 14,180 deaths.

The grant provides immediate funding to further study this ingenious approach and take it immediately to clinical trials, using some of the existing facilities at Roswell Park. It also allows the cancer center to retain researchers and fund some new positions, while potentially creating opportunities for commercial development.

Read more from the original source:
Major grant rewards Roswell Park for innovative research into immunotherapy

Posted in New York Stem Cells | Comments Off on Major grant rewards Roswell Park for innovative research into immunotherapy

What makes pancreatic cancer so aggressive? New study sheds light

Posted: January 16, 2015 at 5:54 am

IMAGE:This is Diane M. Simeone, M.D., University of Michigan Comprehensive Cancer Center. view more

Credit: University of Michigan Comprehensive Cancer Center

ANN ARBOR, Mich. - New research from the University of Michigan Comprehensive Cancer Center helps explain why pancreatic cancer is so lethal, with fewer than a third of patients surviving even early stage disease.

The researchers found a gene known to be involved in nearly 90 percent of pancreatic cancers promotes cancer growth and spread. The gene, ATDC, plays a key role in how a tumor progresses from a preinvasive state to an invasive cancer to metastatic cancer.

"We know that patients with the earliest stage of pancreatic cancer have a survival rate of only 30 percent. This suggests that even in that very early stage of invasive cancer there are already cells that have spread to distant parts of the body," says study author Diane M. Simeone, M.D., director of the Pancreatic Cancer Center at the University of Michigan Comprehensive Cancer Center.

"This study sheds important light on what it is about pancreatic cancer that makes it so aggressive early in the game," she adds. The study appears Jan. 15 in Genes and Development.

Researchers used a mouse model to replicate pancreatic cancer as it appears in humans. They also studied pancreatic cancer tissue samples and samples of pre-invasive pancreatic lesions. They found ATDC was expressed in a subset of the pre-invasive cells and played a role in the development of pancreatic cancer stem cells, the small number of cells in a tumor that fuel its growth and spread. This suggests that ATDC promotes a tumor's invasiveness and spread early in the course of disease.

The researchers suspect that ATDC may be a potent drug target. No drugs currently exist to target this pathway in part because researchers do not understand the crystal structure of the protein. Simeone's team, working with the University of Michigan Center for Structural Biology has made crystals of the protein and begun to create a three-dimensional structure that they can use as a model for drug development.

Preliminary data suggests that ATDC may also play a role in other cancer types, including bladder, ovarian, colorectal and lung cancers and multiple myeloma. But, Simeone notes, it's particularly critical to find new treatment options for pancreatic cancer. About 46,400 Americans will be diagnosed with pancreatic cancer this year, and more than 39,000 will die of the disease. Pancreatic cancer is expected to become the second-leading cause of cancer death in the United States by 2030.

###

See the original post here:
What makes pancreatic cancer so aggressive? New study sheds light

Posted in Michigan Stem Cells | Comments Off on What makes pancreatic cancer so aggressive? New study sheds light

Live imaging captures how blood stem cells take root in the body

Posted: January 16, 2015 at 5:52 am

17 hours ago Blood stem cell en route to taking root in a zebrafish. Credit: Boston Children's Hospital

A see-through zebrafish and enhanced imaging provide the first direct glimpse of how blood stem cells take root in the body to generate blood. Reporting online in the journal Cell today, researchers in Boston Children's Hospital's Stem Cell Research Program describe a surprisingly dynamic system that offers several clues for improving bone marrow transplants in patients with cancer, severe immune deficiencies and blood disorders, and for helping those transplants "take."

The steps are detailed in an animation narrated by senior investigator Leonard Zon, MD, director of the Stem Cell Research Program (see below).

"The same process occurs during a bone marrow transplant as occurs in the body naturally," says Zon. "Our direct visualization gives us a series of steps to target, and in theory we can look for drugs that affect every step of that process."

"Stem cell and bone marrow transplants are still very much a black boxcells are introduced into a patient and later on we can measure recovery of their blood system, but what happens in between can't be seen," says Owen Tamplin, PhD, the paper's co-first author. "Now we have a system where we can actually watch that middle step. "

The blood system's origins

It had already been known that blood stem cells bud off from cells in the aorta, then circulate in the body until they find a "niche" where they're prepped for their future job creating blood for the body. For the first time, the researchers reveal how this niche forms, using time-lapse imaging of naturally transparent zebrafish embryos and a genetic trick that tagged the stem cells green.

On arrival in its niche (in the zebrafish, this is in the tail), the newborn blood stem cell attaches itself to the blood vessel wall. There, chemical signals prompt it to squeeze itself through the wall and into a space just outside the blood vessel.

This video is not supported by your browser at this time.

"In that space, a lot of cells begin to interact with it," says Zon. Nearby endothelial (blood-vessel) cells wrap themselves around it: "We think that is the beginning of making a stem cell happy in its niche, like a mother cuddling a baby."

View post:
Live imaging captures how blood stem cells take root in the body

Posted in Illinois Stem Cells | Comments Off on Live imaging captures how blood stem cells take root in the body

Bone stem cells shown to regenerate bones and cartilage in adult mice

Posted: January 16, 2015 at 5:50 am

IMAGE:The osteochondroretricular stem cell, a newly identified type of bone stem cell that appears to be vital to skeletal development and may provide the basis for novel treatments for osteoarthritis,... view more

Credit: Laboratory of Dr. Timothy Wang

NEW YORK, NY (January 15, 2015) - A stem cell capable of regenerating both bone and cartilage has been identified in bone marrow of mice. The discovery by researchers at Columbia University Medical Center (CUMC) is reported today in the online issue of the journal Cell.

The cells, called osteochondroreticular (OCR) stem cells, were discovered by tracking a protein expressed by the cells. Using this marker, the researchers found that OCR cells self-renew and generate key bone and cartilage cells, including osteoblasts and chondrocytes. Researchers also showed that OCR stem cells, when transplanted to a fracture site, contribute to bone repair.

"We are now trying to figure out whether we can persuade these cells to specifically regenerate after injury. If you make a fracture in the mouse, these cells will come alive again, generate both bone and cartilage in the mouse--and repair the fracture. The question is, could this happen in humans," says Siddhartha Mukherjee, MD, PhD, assistant professor of medicine at CUMC and a senior author of the study.

The researchers believe that OCR stem cells will be found in human bone tissue, as mice and humans have similar bone biology. Further study could provide greater understanding of how to prevent and treat osteoporosis, osteoarthritis, or bone fractures.

"Our findings raise the possibility that drugs or other therapies can be developed to stimulate the production of OCR stem cells and improve the body's ability to repair bone injury--a process that declines significantly in old age," says Timothy C. Wang, MD, the Dorothy L. and Daniel H. Silberberg Professor of Medicine at CUMC, who initiated this research. Previously, Dr. Wang found an analogous stem cell in the intestinal tract and observed that it was also abundant in the bone.

"These cells are particularly active during development, but they also increase in number in adulthood after bone injury," says Gerard Karsenty, MD, PhD, the Paul A. Marks Professor of Genetics and Development, chair of the Department of Genetics & Development, and a member of the research team.

The study also showed that the adult OCRs are distinct from mesenchymal stem cells (MSCs), which play a role in bone generation during development and adulthood. Researchers presumed that MSCs were the origin of all bone, cartilage, and fat, but recent studies have shown that these cells do not generate young bone and cartilage. The CUMC study suggests that OCR stem cells actually fill this function and that both OCR stems cells and MSCs contribute to bone maintenance and repair in adults.

The researchers also suspect that OCR cells may play a role in soft tissue cancers.

Read the original here:
Bone stem cells shown to regenerate bones and cartilage in adult mice

Posted in Washington Stem Cells | Comments Off on Bone stem cells shown to regenerate bones and cartilage in adult mice

Stanford researchers isolate stem cell that gives rise to bones, cartilage in mice

Posted: January 16, 2015 at 5:44 am

Researchers at the Stanford University School of Medicine have discovered the stem cell in mice that gives rise to bone, cartilage and a key part of bone marrow called the stroma.

In addition, the researchers have charted the chemical signals that can create skeletal stem cells and steer their development into each of these specific tissues. The discovery sets the stage for a wide range of potential therapies for skeletal disorders such as bone fractures, brittle bones, osteosarcoma or damaged cartilage.

A paper describing the findings will be published Jan. 15 in Cell.

"Millions of times a year, orthopedic surgeons see torn cartilage in a joint and have to take it out because cartilage doesn't heal well, but that lack of cartilage predisposes the patient to arthritis down the road," said Michael Longaker, MD, a professor of plastic and reconstructive surgery at Stanford and a senior author of the paper. "This research raises the possibility that we can create new skeletal stem cells from patients' own tissues and use them to grow new cartilage." Longaker is also co-director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine.

An intensive search

The researchers started by focusing on groups of cells that divide rapidly at the ends of mouse bones, and then showed that these collections of cells could form all parts of bone: the bone itself, cartilage and the stroma -- the spongy tissue at the center of bones that helps hematopoietic stem cells turn into blood and immune cells. Through extensive effort, they then identified a single type of cell that could, by itself, form all these elements of the skeleton.

The scientists then went much further, mapping the developmental tree of skeletal stem cells to track exactly how they changed into intermediate progenitor cells and eventually each type of skeletal tissue.

"Mapping the tree led to an in-depth understanding of all the genetic switches that have to be flipped in order to give rise to more specific progenitors and eventually highly specialized cells," said postdoctoral scholar Charles Chan, PhD, who shares lead authorship of the paper with postdoctoral scholar David Lo, MD, graduate student James Chen and research assistant Elly Eun Young Seo. With that information, the researchers were able to find factors that, when provided in the right amount and at the right time, would steer the development of skeletal stem cells into bone, cartilage or stromal cells.

"If this is translated into humans, we then have a way to isolate skeletal stem cells and rescue cartilage from wear and tear or aging, repair bones that have nonhealing fractures and renew the bone marrow niche in those who have had it damaged in one way or another," said Irving Weissman, MD, professor of pathology and of developmental biology, who directs the Stanford Institute for Stem Cell Biology and Regenerative Medicine. Weissman, the other senior author of the paper, also holds the Virginia and Daniel K. Ludwig Professorship in Clinical Investigation in Cancer Research.

Reprogramming fat cells

Go here to see the original:
Stanford researchers isolate stem cell that gives rise to bones, cartilage in mice

Posted in Cell Medicine | Comments Off on Stanford researchers isolate stem cell that gives rise to bones, cartilage in mice

Page 1,885«..1020..1,8841,8851,8861,887..1,8901,900..»